Investing.com – U.S. stocks were lower after the close on Tuesday, as losses in the Oil & Gas, Technology and Utilities sectors led shares lower. At the close in NYSE, the Dow...
Investing.com – U.S. stocks were lower after the close on Monday, as losses in the Oil & Gas, Financials and Basic Materials sectors led shares lower. At the close in NYSE, the...
Investing.com – U.S. stocks were lower after the close on Friday, as losses in the Oil & Gas, Consumer Services and Healthcare sectors led shares lower. At the close in NYSE, the...
Bio-Path Holdings, Inc. (NASDAQ:BPTH) announced positive interim data from phase II study (BP1001-201) on its lead pipeline candidate — prexigebersen — in combination...
With the Q1 cycle nearing its end, the earnings picture is becoming increasingly clear. While the going looked tough at the onset of the last month, that scenario has changed over...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Moving Averages||Strong Sell||Strong Sell||Sell||Strong Sell||Strong Sell|
|Technical Indicators||Strong Sell||Strong Sell||Strong Sell||Strong Sell||Sell|
|Summary||Strong Sell||Strong Sell||Strong Sell||Strong Sell||Strong Sell|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Tri-Star Bullish||30||2||Nov 14, 2019 12:00PM|
|Tri-Star Bullish||15||3||Nov 14, 2019 12:15PM|
|Dark Cloud Cover||5H||4||Nov 12, 2019 07:00AM|
Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification. Its lead drug candidate, Liposomal Grb2 (BP1001), targets the protein Growth factor receptor-bound protein 2 (Grb2). Its other liposome delivered antisense drug candidate, Liposomal Bcl2 (BP1002), targets the protein B-cell lymphoma 2 (Bcl2). BP1001 is in Phase II clinical trials for acute myeloid leukemia, and for blast phase and accelerated phase chronic myelogenous leukemia. BP1002 is intended to target the lymphoma and certain solid tumor markets. BP1001 is also in preclinical studies for solid tumors, including triple negative breast cancer and inflammatory breast cancer.Read More
|National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States)||$500||Start Trading|
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
|Securities Investor Protection Corporation (United States)||$0||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.